프레가발린 시장 : 세계 예측(2026-2032년)

The Pregabalin Market is projected to grow by USD 2.24 billion at a CAGR of 8.08% by 2032.

Pregabalin is a widely used gabapentinoid medicine indicated in many jurisdictions for neuropathic pain, fibromyalgia, partial-onset seizures as adjunctive therapy, and generalized anxiety disorder where approved. Its market relevance is anchored in the growing clinical burden of diabetes-related neuropathy, postherpetic neuralgia, spinal cord injury pain, epilepsy, and chronic pain syndromes, alongside increased attention to multimodal pain management and reduced reliance on opioid therapy. The pregabalin landscape is shaped by patent expirations, broad generic availability, evolving prescribing controls, pharmacovigilance requirements, and payer scrutiny of long-term use. Demand is also influenced by population aging, diabetes prevalence, expanded diagnosis of neuropathic pain, and access to primary care, neurology, psychiatry, and pain management services. However, industry participants must navigate safety concerns, including dizziness, somnolence, edema, weight gain, respiratory depression risks when combined with central nervous system depressants, and misuse potential that has prompted tighter scheduling or monitoring in several countries. For stakeholders across active pharmaceutical ingredients, finished dosage forms, distribution, and clinical care pathways, success increasingly depends on quality assurance, regulatory compliance, responsible promotion, real-world evidence, and patient-centered adherence support.

Transformative Shifts in the Pregabalin Landscape

The pregabalin landscape is undergoing structural change as healthcare systems balance access to effective neuropathic pain and seizure therapies with stronger controls on inappropriate use. Genericization has intensified price competition and broadened availability, making manufacturing efficiency, bioequivalence reliability, supply continuity, and differentiated formulations more important than brand recognition. Regulatory agencies and clinical guideline bodies are also reshaping utilization by emphasizing careful patient selection, dose titration, renal-dose adjustment, tapering strategies, and monitoring for dependence or misuse. In parallel, pain care is moving toward integrated pathways that combine pharmacological therapy with physical rehabilitation, psychological support, diabetes management, and digital follow-up. Pharmacies and prescribers are increasingly expected to identify high-risk combinations, particularly concurrent use with opioids, benzodiazepines, alcohol, or other sedatives. Another major shift is the growing role of real-world evidence, as payers and health systems examine persistence, adverse events, switching behavior, and outcomes across diverse patient groups. These changes are pushing industry leaders to move beyond volume-led strategies and focus on responsible access, supply chain resilience, evidence generation, and compliance-led commercialization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the pregabalin value chain, from drug safety monitoring to manufacturing quality and clinical decision support. In pharmacovigilance, AI-enabled natural language processing can help screen adverse event reports, medical literature, electronic health records, and call-center narratives for signals related to sedation, falls, respiratory depression, misuse, withdrawal symptoms, and drug interactions. In manufacturing, machine learning can support process analytical technology, batch deviation detection, predictive maintenance, and quality trend analysis for active pharmaceutical ingredient and finished dosage production. In clinical settings, AI-assisted tools may help identify patients with neuropathic pain patterns, flag renal impairment requiring dose adjustment, and detect high-risk co-prescribing combinations. AI can also strengthen adherence analytics by using pharmacy refill patterns and digital health engagement to identify patients at risk of discontinuation or unsafe escalation. The cumulative impact is not simply automation; it is the creation of faster, more auditable systems for safety, compliance, and patient support. Nevertheless, implementation must be governed by validated datasets, privacy protections, explainable models, and clinical oversight to avoid bias, inappropriate prescribing prompts, or overreliance on algorithmic recommendations.

Key Regional Insights

In Asia-Pacific, pregabalin adoption is supported by large patient populations, rising diabetes burden, expanding generic manufacturing capacity, and growing access to neurology and pain services, with China, India, Japan, South Korea, and Australia demonstrating distinct regulatory and reimbursement pathways. North America remains highly shaped by controlled-substance frameworks, payer utilization management, opioid-sparing pain strategies, and strong pharmacovigilance expectations, particularly in the United States and Canada where prescribing data, dispensing oversight, and risk communication influence utilization. Latin America is characterized by improving access to generic medicines and increasing recognition of neuropathic pain, though affordability, fragmented healthcare delivery, and uneven specialist access continue to affect treatment continuity. Europe reflects mature regulatory oversight, extensive generic competition, and national-level guidance on gabapentinoid prescribing, with several countries tightening controls because of misuse and dependence concerns. The Middle East shows expanding access through hospital systems, specialist clinics, and government procurement channels, while prescribing practices are influenced by controlled medicine policies and variability in insurance coverage. Africa presents a more uneven landscape, where pregabalin availability depends on essential medicine procurement priorities, private-sector access, local registration status, affordability, and clinician capacity to diagnose and manage neuropathic pain and epilepsy. Across all regions, the most durable opportunities are linked to quality-assured generics, responsible distribution, patient education, and alignment with national medicine safety policies.

Key Group Insights

Within ASEAN, pregabalin dynamics are shaped by diverse regulatory maturity, expanding diabetes care, growing private healthcare access, and an active generic medicines environment, with affordability and consistent supply remaining central to adoption. The GCC countries benefit from strong hospital infrastructure, centralized procurement, and increasing specialty care capacity, while strict controlled medicine rules and formulary decisions guide availability and prescribing behavior. In the European Union, harmonized regulatory standards coexist with country-specific reimbursement and prescribing controls, creating a landscape where pharmacovigilance, bioequivalence, serialization, and responsible use policies are essential competitive requirements. BRICS countries collectively represent a broad range of pregabalin demand drivers, including large neuropathic pain and epilepsy patient pools, domestic pharmaceutical manufacturing capabilities, expanding insurance coverage, and variable enforcement of prescription controls. G7 markets are characterized by advanced regulatory oversight, widespread generic penetration, mature pharmacovigilance systems, and strong payer focus on appropriate prescribing, particularly for chronic pain populations and patients using concomitant sedatives. NATO member countries overlap substantially with regulated North American and European markets, where medicine security, supply chain resilience, quality compliance, and controlled-substance governance are increasingly relevant to pharmaceutical procurement and continuity planning. Across these groups, the common strategic theme is the shift from basic product availability toward evidence-backed, quality-led, and safety-conscious pregabalin access.

Key Country Insights

In the United States, pregabalin use is shaped by generic availability, state-level monitoring, payer prior authorization, and heightened awareness of gabapentinoid risks when combined with opioids or other sedatives. Canada similarly emphasizes controlled access, prescription monitoring in multiple provinces, and careful prescribing for chronic pain and seizure-related indications. Mexico and Brazil demonstrate growing generic access and a significant need for neuropathic pain treatment, particularly in diabetes-related complications, although affordability and healthcare fragmentation influence continuity of therapy. The United Kingdom has placed pregabalin under stricter controlled drug scheduling, making safe prescribing, tapering, and misuse prevention central to clinical practice. Germany, France, Italy, and Spain operate within mature European regulatory and reimbursement systems where generic competition is strong and prescribing guidance increasingly emphasizes risk assessment and appropriate duration of therapy. Russia has demand drivers linked to neurology, pain management, and epilepsy care, with access shaped by domestic registration, procurement, and pricing policies. China combines a large patient base with expanding domestic pharmaceutical production and evolving volume-based procurement mechanisms that place strong pressure on quality and cost efficiency. India is a major generic manufacturing hub with broad domestic use, while prescription discipline and pharmacovigilance maturity remain important areas of policy attention. Japan maintains rigorous regulatory standards and an aging population with neuropathic pain needs, supporting demand for clinically well-characterized therapies. Australia regulates pregabalin through national reimbursement and prescribing controls, with attention to misuse, dependence, and co-prescribing risks. South Korea combines advanced healthcare infrastructure, strong insurance coverage, and high expectations for quality, bioequivalence, and post-marketing safety monitoring. Across these countries, industry performance depends on regulatory readiness, supply reliability, evidence-based positioning, and support for responsible clinical use.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize responsible access strategies that align commercial growth with patient safety and regulatory expectations. First, strengthen pharmacovigilance systems to capture misuse, dependence, withdrawal, respiratory depression, falls, and high-risk co-prescribing signals in near real time. Second, invest in manufacturing excellence, including robust supplier qualification, impurity control, bioequivalence consistency, serialization compliance, and resilient sourcing for active pharmaceutical ingredients. Third, support prescriber and pharmacist education focused on renal dosing, gradual titration, tapering, interaction risks, and patient counseling. Fourth, develop real-world evidence programs that evaluate adherence, treatment persistence, safety outcomes, and patient-reported pain or function improvements without making unsupported comparative claims. Fifth, tailor access strategies to local reimbursement rules, controlled-substance requirements, and formulary evidence expectations. Sixth, use digital tools responsibly to improve medication reminders, refill coordination, and adverse event reporting while protecting patient privacy. Finally, prepare for increased regulatory scrutiny by maintaining transparent documentation, compliant promotional practices, and proactive engagement with healthcare stakeholders on safe and appropriate pregabalin use.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified public-domain and industry-relevant sources. Inputs include regulatory agency communications, prescribing information, medicine scheduling updates, pharmacovigilance advisories, clinical practice guidelines, peer-reviewed literature, public health statistics on diabetes, neuropathic pain and epilepsy, and healthcare access indicators. Regional, group, and country insights are synthesized through comparative assessment of regulatory frameworks, generic medicine policies, reimbursement practices, controlled-substance rules, healthcare infrastructure, and disease burden indicators. The analysis excludes market sizing, market share, revenue estimation, and forecasting, and instead focuses on qualitative and evidence-backed factors influencing pregabalin availability, utilization, safety, and strategic positioning. Data points are interpreted through triangulation across multiple credible sources to reduce single-source bias, with emphasis on consistency, recency, and relevance to pharmaceutical decision-making. The methodology also considers real-world constraints such as affordability, supply chain reliability, prescriber behavior, pharmacy controls, and patient adherence. This approach provides a practical, compliance-aware view of the pregabalin landscape for executives, strategists, manufacturers, distributors, and healthcare stakeholders.

Conclusion

Pregabalin remains an important therapy across neuropathic pain, epilepsy-related adjunctive treatment, fibromyalgia, and anxiety-related indications where approved, but its future is defined by responsible utilization rather than simple expansion. Generic availability has improved access, yet safety concerns, misuse potential, payer controls, and evolving prescribing guidelines require disciplined participation. Regional and country differences in regulation, reimbursement, healthcare infrastructure, and disease burden create varied pathways for adoption, making localized strategy essential. Artificial intelligence is set to strengthen pharmacovigilance, manufacturing quality, and clinical support, provided that governance, validation, and privacy safeguards are embedded from the outset. The most resilient industry leaders will be those that combine reliable supply, quality manufacturing, evidence generation, compliant engagement, and patient safety initiatives. In a landscape where regulators, payers, clinicians, and patients are increasingly focused on measurable value and harm reduction, pregabalin strategies must be built around trust, transparency, and clinically appropriate access.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pregabalin Market, by Dosage Form

• 7.1. Introduction
• 7.2. Capsule
• 7.3. Oral Solution

8. Pregabalin Market, by Drug Class

• 8.1. Introduction
• 8.2. Anticonvulsants
• 8.3. Fibromyalgia Agents
• 8.4. Neuropathic Pain Therapeutics

9. Pregabalin Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Pregabalin Market, by Application

• 10.1. Introduction
• 10.2. Epilepsy
• 10.3. Fibromyalgia
• 10.4. Generalized Anxiety Disorder
• 10.5. Neuropathic Pain

11. Pregabalin Market, by End User

• 11.1. Introduction
• 11.2. Home Care Settings
• 11.3. Hospitals
• 11.4. Specialty Clinics

12. Pregabalin Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Pregabalin Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Pregabalin Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Alembic Pharmaceuticals Limited
• 16.2. Almelo Private Limited
• 16.3. Amneal Pharmaceuticals LLC
• 16.4. Apotex Inc.
• 16.5. Aurobindo Pharma Limited
• 16.6. BAL Pharma Ltd.
• 16.7. Cipla Limited
• 16.8. Hetero Healthcare Limited
• 16.9. Hikal Limited
• 16.10. Indoco Remedies Ltd.
• 16.11. Intas Pharmaceuticals Ltd.
• 16.12. Jiangxi Jinfeng Pharmaceutical Co., Ltd.
• 16.13. Jubilant Generics Limited
• 16.14. Lupin Limited
• 16.15. Medley Pharmaceuticals Ltd.
• 16.16. MSN Laboratories
• 16.17. Mylan N.V.
• 16.18. Novartis AG
• 16.19. Pfizer Inc.
• 16.20. Strides Pharma Science Limited
• 16.21. Sun Pharmaceutical Industries Ltd.
• 16.22. Suzhou Lixin Pharmaceutical Co., Ltd.
• 16.23. Teva Pharmaceutical Industries Ltd.
• 16.24. Unichem Laboratories Ltd.
• 16.25. Zydus Lifesciences Limited